Periodic Reporting for period 1 - ADAMtx (ADAMtx: Development of Alzheimer’s immunotherapy by harnessing the natural reparative properties of microglia)
Reporting period: 2019-10-01 to 2021-03-31
Alzheimer's disease is caused by multiple detrimental factors leading to cognitive decline. Currently, no effective treatment exists for this disease, as targeting any single factor could not stop or reverse the disease, as evident in the multiple failures seen in recent clinical trials. The EU-funded ADAMtx project develops novel approaches for comprehensive treatment using advanced single cell genomics and artificial intelligence. Previously, we have discovered immuno-competent brain microglia cells (disease associated microglia) that specifically sense and fight neurodegenerative diseases. In the current project, we have developed several different strategies and immunotherapy molecules that stimulate the activity in these potent immune cells, with promising potential of therapeutic manipulation of Alzheimer's disease.